Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Topline results from Janssen bapineuzumab Phase 3 trial on mild-to-moderate Alzheimer's

Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301).

7 Aug 2012

AD hits hardest among people in their 60s and 70s

The greatest risk factor for Alzheimer's disease (AD) is advancing age. By age 85, the likelihood of developing the dreaded neurological disorder is roughly 50 percent. But researchers at the University of California, San Diego School of Medicine say AD hits hardest among the "younger elderly" - people in their 60s and 70s - who show faster rates of brain tissue loss and cognitive decline than AD patients 80 years and older.

3 Aug 2012

Mechanism provides beneficial characteristics of energy-burning brown fat to white fat

Columbia University Medical Center (CUMC) researchers have identified a mechanism that can give energy-storing white fat some of the beneficial characteristics of energy-burning brown fat. The findings, based on studies of mice and of human fat tissue, could lead to new strategies for treating obesity and type 2 diabetes.

3 Aug 2012

Potential PD biomarkers identified for sleep behavior disorder

Concomitant olfaction abnormality and increased substantia nigra echogenicity may be preclinical manifestations of parkinsonism in patients with idiopathic rapid eye movement sleep behavior disorder, research suggests.

3 Aug 2012

Affymetrix announces availability of SensationPlus FFPE Amplification and 3' IVT Labeling Kit

Affymetrix, Inc. announced today the availability of SensationPlus FFPE Amplification and 3' IVT Labeling Kit (SensationPlus FFPE Reagent Kit), consisting of RNA amplification and labeling modules, to enable gene expression profiling of formalin-fixed, paraffin-embedded (FFPE) samples on GeneChip 3' IVT arrays and Almac XcelTM Array for disease clinical research and retrospective studies.

3 Aug 2012

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Breast cancer is the most important cancer for women in the developed world. About 20% of all patients diagnosed with breast cancer die of metastatic disease.

1 Aug 2012

Researchers discover new approach to treat two lethal metastatic cancers

A potentially powerful new approach to treating two lethal metastatic cancers - triple negative breast cancer and clear cell renal cell carcinoma, the most common form of kidney cancer - has been discovered by researchers at Mayo Clinic in Florida.

1 Aug 2012

Affymetrix second quarter total revenue increases to $66.4 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2012. Total revenue for the quarter was $66.4 million, including approximately $1.4 million in revenue from eBioscience following the close of Affymetrix's acquisition of the company on June 25. This compares to total revenue of $64.7 million for the same period of 2011.

31 Jul 2012

Population Genetics validates GenomePooling™ for cancer

Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling™ method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

31 Jul 2012

GenomePooling™ method is sensitive and accurate

31 Jul 2012

Brain injury patterns predict outcomes in oxygen-starved infants

Patterns of brain injury in babies with neonatal hypoxic–ischemic encephalopathy predict survival and disability in late infancy, show study findings.

31 Jul 2012

Study sheds light on complexities of cancer genetics

30 Jul 2012

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Vermillion, Inc., a leading molecular diagnostics company, today announced positive results from a new prospective, multi-center clinical study of its ovarian cancer diagnostic OVA1.

30 Jul 2012

Fruit flies help pinpoint genetic changes that spell cancer

By studying fruit flies, scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have successfully devised a fast and cost-saving way to uncover genetic changes that have a higher potential to cause cancer. With this new approach, researchers will now be able to rapidly distinguish the range of genetic changes that are causally linked to cancer (i.e. "driver" mutations) versus those with limited impact on cancer progression.

30 Jul 2012

Potential biomarker to predict lung cancer patients' response to chemotherapy

Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports.

27 Jul 2012

LSDF announces $570,000 in awards to support commercialization of new health-related products

The Life Sciences Discovery Fund (LSDF) today announced nearly $570,000 in awards in its inaugural corporate grant program to support commercialization of new health and health-care products by four early-stage Washington-based companies.

25 Jul 2012

BD youth show altered frontal lobe bioenergetic metabolism

Results from a US study suggest that depressed unmedicated adolescents with bipolar disorder (BD) have altered frontal lobe mitochondrial function.

24 Jul 2012

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

SuppreMol GmbH, an autoimmune disease specialist, today announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA). SuppreMol will advance preclinical development of SM401 for treatment of RA. Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.

24 Jul 2012

HALO, UND enter agreement to develop biomarkers for early detection of breast cancer

HALO Healthcare, Inc., a provider of innovative diagnostic solutions for women's breast care announced that it has signed a definitive license agreement with the University of North Dakota (UND) to develop biomarkers for the early detection of breast cancer.

23 Jul 2012

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled "Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer."

23 Jul 2012

Biomarker News and Research

Further Reading

Topline results from Janssen bapineuzumab Phase 3 trial on mild-to-moderate Alzheimer's

AD hits hardest among people in their 60s and 70s

Mechanism provides beneficial characteristics of energy-burning brown fat to white fat

Potential PD biomarkers identified for sleep behavior disorder

Affymetrix announces availability of SensationPlus FFPE Amplification and 3' IVT Labeling Kit

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Researchers discover new approach to treat two lethal metastatic cancers

Affymetrix second quarter total revenue increases to $66.4 million

Population Genetics validates GenomePooling™ for cancer

GenomePooling™ method is sensitive and accurate

Brain injury patterns predict outcomes in oxygen-starved infants

Study sheds light on complexities of cancer genetics

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Fruit flies help pinpoint genetic changes that spell cancer

Potential biomarker to predict lung cancer patients' response to chemotherapy

LSDF announces $570,000 in awards to support commercialization of new health-related products

BD youth show altered frontal lobe bioenergetic metabolism

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

HALO, UND enter agreement to develop biomarkers for early detection of breast cancer

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News